Provider: Nature Publishing Group
Content: application/x-research-info-systems
TY  - JOUR
AU  - Ferrara, N.
TI  - VEGF and the quest for tumour angiogenesis factors
JA  - Nature Rev. Cancer
PY  - 2002///
VL  - 2
SP  - 795
EP  - 803
M3  - 10.1038/nrc909
N1  - 10.1038/nrc909
UR  - http://dx.doi.org/10.1038/nrc909
ER  -

TY  - JOUR
AU  - Ide, A. G.
AU  - Baker, N. H.
AU  - Warren, S. L.
TI  - Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber
JA  - Am. J. Roentgenol.
PY  - 1939///
VL  - 42
SP  - 891
EP  - 899
ER  -

TY  - JOUR
AU  - Algire, G. H.
AU  - Chalkley, H. W.
AU  - Legallais, F. Y.
AU  - Park, H. D.
TI  - Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants
JA  - J. Natl Cancer Inst.
PY  - 1945///
VL  - 6
SP  - 73
EP  - 85
ER  -

TY  - JOUR
AU  - Folkman, J.
TI  - Tumor angiogenesis: therapeutic implications
JA  - N. Engl. J. Med.
PY  - 1971///
VL  - 285
SP  - 1182
EP  - 1186
ER  -

TY  - JOUR
AU  - Hurwitz, H.
TI  - Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
JA  - N. Engl. J. Med.
PY  - 2004///
VL  - 350
SP  - 2335
EP  - 2342
M3  - 10.1056/NEJMoa032691
N1  - 10.1056/NEJMoa032691
UR  - http://dx.doi.org/10.1056/NEJMoa032691
ER  -

TY  - JOUR
AU  - Gragoudas, E. S.
AU  - Adamis, A. P.
AU  - Cunningham, E. T., 
AU  - Feinsod, M.
AU  - Guyer, D. R.
TI  - Pegaptanib for neovascular age-related macular degeneration
JA  - N. Engl. J. Med.
PY  - 2004///
VL  - 351
SP  - 2805
EP  - 2816
M3  - 10.1056/NEJMoa042760
N1  - 10.1056/NEJMoa042760
UR  - http://dx.doi.org/10.1056/NEJMoa042760
ER  -

TY  - JOUR
AU  - Kerbel, R.
AU  - Folkman, J.
TI  - Clinical translation of angiogenesis inhibitors
JA  - Nature Rev. Cancer
PY  - 2002///
VL  - 2
SP  - 727
EP  - 739
M3  - 10.1038/nrc905
N1  - 10.1038/nrc905
UR  - http://dx.doi.org/10.1038/nrc905
ER  -

TY  - JOUR
AU  - Ferrara, N.
AU  - Gerber, H. P.
AU  - LeCouter, J.
TI  - The biology of VEGF and its receptors
JA  - Nature Med.
PY  - 2003///
VL  - 9
SP  - 669
EP  - 676
M3  - 10.1038/nm0603-669
N1  - 10.1038/nm0603-669
UR  - http://dx.doi.org/10.1038/nm0603-669
ER  -

TY  - JOUR
AU  - Yancopoulos, G. D.
TI  - Vascular-specific growth factors and blood vessel formation
JA  - Nature
PY  - 2000///
VL  - 407
SP  - 242
EP  - 248
M3  - 10.1038/35025215
N1  - 10.1038/35025215
UR  - http://dx.doi.org/10.1038/35025215
ER  -

TY  - JOUR
AU  - Ferrara, N.
TI  - Vascular endothelial growth factor: basic science and clinical progress
JA  - Endocr. Rev.
PY  - 2004///
VL  - 25
SP  - 581
EP  - 611
M3  - 10.1210/er.2003-0027
N1  - 10.1210/er.2003-0027
UR  - http://dx.doi.org/10.1210/er.2003-0027
ER  -

TY  - JOUR
AU  - Hattori, K.
TI  - Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment
JA  - Nature Med.
PY  - 2002///
VL  - 8
SP  - 841
EP  - 849
M3  - 10.1038/nm740
N1  - 10.1038/nm740
UR  - http://dx.doi.org/10.1038/nm740
ER  -

TY  - JOUR
AU  - Gerber, H. -P.
TI  - Vascular endothelial growth factor regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
JA  - Nature
PY  - 2002///
VL  - 417
SP  - 954
EP  - 958
M3  - 10.1038/nature00821
N1  - 10.1038/nature00821
UR  - http://dx.doi.org/10.1038/nature00821
ER  -

TY  - JOUR
AU  - Luttun, A.
TI  - Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
JA  - Nature Med.
PY  - 2002///
VL  - 8
SP  - 831
EP  - 840
M3  - 10.1038/nm731
N1  - 10.1038/nm731
UR  - http://dx.doi.org/10.1038/nm731
ER  -

TY  - JOUR
AU  - Hiratsuka, S.
TI  - MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis
JA  - Cancer Cell
PY  - 2002///
VL  - 2
SP  - 289
EP  - 300
M3  - 10.1016/S1535-6108(02)00153-8
N1  - 10.1016/S1535-6108(02)00153-8
UR  - http://dx.doi.org/10.1016/S1535-6108(02)00153-8
ER  -

TY  - JOUR
AU  - LeCouter, J.
TI  - Angiogenesis-independent endothelial protection of liver: role of VEGFR-1
JA  - Science
PY  - 2003///
VL  - 299
SP  - 890
EP  - 893
M3  - 10.1126/science.1079562
N1  - 10.1126/science.1079562
UR  - http://dx.doi.org/10.1126/science.1079562
ER  -

TY  - JOUR
AU  - Wey, J. S.
TI  - Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines
JA  - Cancer
PY  - 2005///
VL  - 104
SP  - 427
EP  - 438
M3  - 10.1002/cncr.21145
N1  - 10.1002/cncr.21145
UR  - http://dx.doi.org/10.1002/cncr.21145
ER  -

TY  - JOUR
AU  - Safran, M.
AU  - Kaelin, W. J., 
TI  - HIF hydroxylation and the mammalian oxygen-sensing pathway
JA  - J. Clin. Invest.
PY  - 2003///
VL  - 111
SP  - 779
EP  - 783
M3  - 10.1172/JCI200318181
N1  - 10.1172/JCI200318181
UR  - http://dx.doi.org/10.1172/JCI200318181
ER  -

TY  - JOUR
AU  - Dvorak, H. F.
TI  - Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
JA  - J. Clin. Oncol.
PY  - 2002///
VL  - 20
SP  - 4368
EP  - 4380
M3  - 10.1200/JCO.2002.10.088
N1  - 10.1200/JCO.2002.10.088
UR  - http://dx.doi.org/10.1200/JCO.2002.10.088
ER  -

TY  - JOUR
AU  - Lonser, R. R.
TI  - von Hippel-Lindau disease
JA  - Lancet
PY  - 2003///
VL  - 361
SP  - 2059
EP  - 2067
M3  - 10.1016/S0140-6736(03)13643-4
N1  - 10.1016/S0140-6736(03)13643-4
UR  - http://dx.doi.org/10.1016/S0140-6736(03)13643-4
ER  -

TY  - JOUR
AU  - Yang, J. C.
TI  - A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer
JA  - N. Engl. J. Med.
PY  - 2003///
VL  - 349
SP  - 427
EP  - 434
M3  - 10.1056/NEJMoa021491
N1  - 10.1056/NEJMoa021491
UR  - http://dx.doi.org/10.1056/NEJMoa021491
ER  -

TY  - JOUR
AU  - Rak, J.
TI  - Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis
JA  - Cancer Res.
PY  - 1995///
VL  - 55
SP  - 4575
EP  - 4580
ER  -

TY  - JOUR
AU  - Brugarolas, J.
AU  - Kaelin, W. G., 
TI  - Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes
JA  - Cancer Cell
PY  - 2004///
VL  - 6
SP  - 7
EP  - 10
M3  - 10.1016/j.ccr.2004.06.020
N1  - 10.1016/j.ccr.2004.06.020
UR  - http://dx.doi.org/10.1016/j.ccr.2004.06.020
ER  -

TY  - JOUR
AU  - Kim, K. J.
TI  - Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
JA  - Nature
PY  - 1993///
VL  - 362
SP  - 841
EP  - 844
M3  - 10.1038/362841a0
N1  - 10.1038/362841a0
UR  - http://dx.doi.org/10.1038/362841a0
ER  -

TY  - JOUR
AU  - Gerber, H. P.
AU  - Ferrara, N.
TI  - Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
JA  - Cancer Res.
PY  - 2005///
VL  - 65
SP  - 671
EP  - 680
ER  -

TY  - JOUR
AU  - Millauer, B.
AU  - Shawver, L. K.
AU  - Plate, K. H.
AU  - Risau, W.
AU  - Ullrich, A.
TI  - Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
JA  - Nature
PY  - 1994///
VL  - 367
SP  - 576
EP  - 579
M3  - 10.1038/367576a0
N1  - 10.1038/367576a0
UR  - http://dx.doi.org/10.1038/367576a0
ER  -

TY  - JOUR
AU  - Prewett, M.
TI  - Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis
JA  - Cancer Res.
PY  - 1999///
VL  - 59
SP  - 5209
EP  - 5218
ER  -

TY  - JOUR
AU  - Wood, J. M.
TI  - PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
JA  - Cancer Res.
PY  - 2000///
VL  - 60
SP  - 2178
EP  - 2189
ER  -

TY  - JOUR
AU  - Gerber, H. P.
AU  - Kowalski, J.
AU  - Sherman, D.
AU  - Eberhard, D. A.
AU  - Ferrara, N.
TI  - Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor
JA  - Cancer Res.
PY  - 2000///
VL  - 60
SP  - 6253
EP  - 6258
ER  -

TY  - JOUR
AU  - Holash, J.
TI  - VEGF-Trap: a VEGF blocker with potent antitumor effects
JA  - Proc. Natl Acad. Sci. USA
PY  - 2002///
VL  - 99
SP  - 11393
EP  - 11398
M3  - 10.1073/pnas.172398299
N1  - 10.1073/pnas.172398299
UR  - http://dx.doi.org/10.1073/pnas.172398299
ER  -

TY  - JOUR
AU  - Inoue, M.
AU  - Hager, J. H.
AU  - Ferrara, N.
AU  - Gerber, H. P.
AU  - Hanahan, D.
TI  - VEGF-A has a critical, non redundant role in angiogenic switching and pancreatic [beta] cell carcinogenesis
JA  - Cancer Cell
PY  - 2002///
VL  - 1
SP  - 193
EP  - 202
M3  - 10.1016/S1535-6108(02)00031-4
N1  - 10.1016/S1535-6108(02)00031-4
UR  - http://dx.doi.org/10.1016/S1535-6108(02)00031-4
ER  -

TY  - JOUR
AU  - Lindhal, P.
AU  - Johansson, B. E.
AU  - Leveen, P.
AU  - Betsholtz, C.
TI  - Pericyte loss and microaneurysm formation in PDGF-B-deficient mice
JA  - Science
PY  - 1997///
VL  - 277
SP  - 242
EP  - 245
M3  - 10.1126/science.277.5323.242
N1  - 10.1126/science.277.5323.242
UR  - http://dx.doi.org/10.1126/science.277.5323.242
ER  -

TY  - JOUR
AU  - Bergers, G.
AU  - Song, S.
AU  - Meyer-Morse, N.
AU  - Bergsland, E.
AU  - Hanahan, D.
TI  - Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
JA  - J. Clin. Invest.
PY  - 2003///
VL  - 111
SP  - 1287
EP  - 1295
M3  - 10.1172/JCI200317929
N1  - 10.1172/JCI200317929
UR  - http://dx.doi.org/10.1172/JCI200317929
ER  -

TY  - JOUR
AU  - Dong, J.
TI  - VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis
JA  - EMBO J.
PY  - 2004///
VL  - 23
SP  - 2800
EP  - 2810
M3  - 10.1038/sj.emboj.7600289
N1  - 10.1038/sj.emboj.7600289
UR  - http://dx.doi.org/10.1038/sj.emboj.7600289
ER  -

TY  - JOUR
AU  - Maisonpierre, P. C.
TI  - Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis
JA  - Science
PY  - 1997///
VL  - 277
SP  - 55
EP  - 60
M3  - 10.1126/science.277.5322.55
N1  - 10.1126/science.277.5322.55
UR  - http://dx.doi.org/10.1126/science.277.5322.55
ER  -

TY  - JOUR
AU  - Oliner, J.
TI  - Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
JA  - Cancer Cell
PY  - 2004///
VL  - 6
SP  - 507
EP  - 516
M3  - 10.1016/j.ccr.2004.09.030
N1  - 10.1016/j.ccr.2004.09.030
UR  - http://dx.doi.org/10.1016/j.ccr.2004.09.030
ER  -

TY  - JOUR
AU  - Carmeliet, P.
AU  - Tessier-Lavigne, M.
TI  - Common mechanisms of nerve and blood vessel wiring
JA  - Nature
PY  - 2005///
VL  - 436
SP  - 193
EP  - 200
M3  - 10.1038/nature03875
N1  - 10.1038/nature03875
UR  - http://dx.doi.org/10.1038/nature03875
ER  -

TY  - JOUR
AU  - Klagsbrun, M.
AU  - Eichmann, A.
TI  - A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis
JA  - Cytokine Growth Factor Rev.
PY  - 2005///
VL  - 16
SP  - 535
EP  - 548
M3  - 10.1016/j.cytogfr.2005.05.002
N1  - 10.1016/j.cytogfr.2005.05.002
UR  - http://dx.doi.org/10.1016/j.cytogfr.2005.05.002
ER  -

TY  - JOUR
AU  - Soker, S.
AU  - Takashima, S.
AU  - Miao, H. Q.
AU  - Neufeld, G.
AU  - Klagsbrun, M.
TI  - Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
JA  - Cell
PY  - 1998///
VL  - 92
SP  - 735
EP  - 745
M3  - 10.1016/S0092-8674(00)81402-6
N1  - 10.1016/S0092-8674(00)81402-6
UR  - http://dx.doi.org/10.1016/S0092-8674(00)81402-6
ER  -

TY  - JOUR
AU  - Pasquale, E. B.
TI  - Eph receptor signalling casts a wide net on cell behaviour
JA  - Nature Rev. Mol. Cell. Biol.
PY  - 2005///
VL  - 6
SP  - 462
EP  - 475
M3  - 10.1038/nrm1662
N1  - 10.1038/nrm1662
UR  - http://dx.doi.org/10.1038/nrm1662
ER  -

TY  - JOUR
AU  - Pandey, A.
AU  - Shao, H.
AU  - Marks, R. M.
AU  - Polverini, P. J.
AU  - Dixit, V. M.
TI  - Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis
JA  - Science
PY  - 1995///
VL  - 268
SP  - 567
EP  - 569
ER  -

TY  - JOUR
AU  - Martiny-Baron, G.
TI  - Inhibition of tumor growth and angiogenesis by soluble EphB4
JA  - Neoplasia
PY  - 2004///
VL  - 6
SP  - 248
EP  - 257
ER  -

TY  - JOUR
AU  - Dobrzanski, P.
TI  - Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist
JA  - Cancer Res.
PY  - 2004///
VL  - 64
SP  - 910
EP  - 919
M3  - 10.1158/0008-5472.CAN-3430-2
N1  - 10.1158/0008-5472.CAN-3430-2
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-3430-2
ER  -

TY  - JOUR
AU  - Wang, B.
TI  - Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity
JA  - Cancer Cell
PY  - 2003///
VL  - 4
SP  - 19
EP  - 29
M3  - 10.1016/S1535-6108(03)00164-8
N1  - 10.1016/S1535-6108(03)00164-8
UR  - http://dx.doi.org/10.1016/S1535-6108(03)00164-8
ER  -

TY  - GEN
AU  - DiPietro, L. A.
TI  - Regulation of Angiogenesis
PY  - 1997///
SP  - 295
EP  - 314
ER  -

TY  - JOUR
AU  - O'Reilly, M. S.
TI  - Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
JA  - Cell
PY  - 1997///
VL  - 88
SP  - 277
EP  - 285
M3  - 10.1016/S0092-8674(00)81848-6
N1  - 10.1016/S0092-8674(00)81848-6
UR  - http://dx.doi.org/10.1016/S0092-8674(00)81848-6
ER  -

TY  - JOUR
AU  - Sund, M.
TI  - Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors
JA  - Proc. Natl Acad. Sci. USA
PY  - 2005///
VL  - 102
SP  - 2934
EP  - 2939
M3  - 10.1073/pnas.0500180102
N1  - 10.1073/pnas.0500180102
UR  - http://dx.doi.org/10.1073/pnas.0500180102
ER  -

TY  - JOUR
AU  - Pike, S. E.
TI  - Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth
JA  - J. Exp. Med.
PY  - 1998///
VL  - 188
SP  - 2349
EP  - 2356
M3  - 10.1084/jem.188.12.2349
N1  - 10.1084/jem.188.12.2349
UR  - http://dx.doi.org/10.1084/jem.188.12.2349
ER  -

TY  - JOUR
AU  - Watanabe, K.
TI  - Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis
JA  - J. Clin. Invest.
PY  - 2004///
VL  - 114
SP  - 898
EP  - 907
M3  - 10.1172/JCI200421152
N1  - 10.1172/JCI200421152
UR  - http://dx.doi.org/10.1172/JCI200421152
ER  -

TY  - JOUR
AU  - Nyberg, P.
AU  - Xie, L.
AU  - Kalluri, R.
TI  - Endogenous inhibitors of angiogenesis
JA  - Cancer Res.
PY  - 2005///
VL  - 65
SP  - 3967
EP  - 3979
M3  - 10.1158/0008-5472.CAN-04-2427
N1  - 10.1158/0008-5472.CAN-04-2427
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-04-2427
ER  -

TY  - JOUR
AU  - Asahara, T.
TI  - Isolation of putative progenitor endothelial cells for angiogenesis
JA  - Science
PY  - 1997///
VL  - 275
SP  - 964
EP  - 967
M3  - 10.1126/science.275.5302.964
N1  - 10.1126/science.275.5302.964
UR  - http://dx.doi.org/10.1126/science.275.5302.964
ER  -

TY  - JOUR
AU  - Takahashi, T.
TI  - Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
JA  - Nature Med.
PY  - 1999///
VL  - 5
SP  - 434
EP  - 438
M3  - 10.1038/7434
N1  - 10.1038/7434
UR  - http://dx.doi.org/10.1038/7434
ER  -

TY  - JOUR
AU  - Lyden, D.
TI  - Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
JA  - Nature Med.
PY  - 2001///
VL  - 7
SP  - 1194
EP  - 1201
M3  - 10.1038/nm1101-1194
N1  - 10.1038/nm1101-1194
UR  - http://dx.doi.org/10.1038/nm1101-1194
ER  -

TY  - JOUR
AU  - Heissig, B.
TI  - Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand
JA  - Cell
PY  - 2002///
VL  - 109
SP  - 625
EP  - 637
M3  - 10.1016/S0092-8674(02)00754-7
N1  - 10.1016/S0092-8674(02)00754-7
UR  - http://dx.doi.org/10.1016/S0092-8674(02)00754-7
ER  -

TY  - JOUR
AU  - Ruzinova, M. B.
TI  - Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors
JA  - Cancer Cell
PY  - 2003///
VL  - 4
SP  - 277
EP  - 289
M3  - 10.1016/S1535-6108(03)00240-X
N1  - 10.1016/S1535-6108(03)00240-X
UR  - http://dx.doi.org/10.1016/S1535-6108(03)00240-X
ER  -

TY  - JOUR
AU  - De Palma, M.
AU  - Venneri, M. A.
AU  - Roca, C.
AU  - Naldini, L.
TI  - Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells
JA  - Nature Med.
PY  - 2003///
VL  - 9
SP  - 789
EP  - 795
M3  - 10.1038/nm871
N1  - 10.1038/nm871
UR  - http://dx.doi.org/10.1038/nm871
ER  -

TY  - JOUR
AU  - Peters, B. A.
TI  - Contribution of bone marrow-derived endothelial cells to human tumor vasculature
JA  - Nature Med.
PY  - 2005///
VL  - 11
SP  - 261
EP  - 262
M3  - 10.1038/nm1200
N1  - 10.1038/nm1200
UR  - http://dx.doi.org/10.1038/nm1200
ER  -

TY  - JOUR
AU  - Shaked, Y.
TI  - Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis
JA  - Cancer Cell
PY  - 2005///
VL  - 7
SP  - 101
EP  - 111
M3  - 10.1016/j.ccr.2004.11.023
N1  - 10.1016/j.ccr.2004.11.023
UR  - http://dx.doi.org/10.1016/j.ccr.2004.11.023
ER  -

TY  - JOUR
AU  - Gasparini, G.
AU  - Longo, R.
AU  - Fanelli, M.
AU  - Teicher, B. A.
TI  - Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions
JA  - J. Clin. Oncol.
PY  - 2005///
VL  - 23
SP  - 1295
EP  - 1311
M3  - 10.1200/JCO.2005.10.022
N1  - 10.1200/JCO.2005.10.022
UR  - http://dx.doi.org/10.1200/JCO.2005.10.022
ER  -

TY  - JOUR
AU  - Browder, T.
TI  - Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
JA  - Cancer Res.
PY  - 2000///
VL  - 60
SP  - 1878
EP  - 1886
ER  -

TY  - JOUR
AU  - Klement, G.
TI  - Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
JA  - J. Clin. Invest.
PY  - 2000///
VL  - 105
SP  - R15
EP  - R24
ER  -

TY  - JOUR
AU  - Sweeney, C. J.
TI  - The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors
JA  - Cancer Res.
PY  - 2001///
VL  - 61
SP  - 3369
EP  - 3372
ER  -

TY  - JOUR
AU  - Bertolini, F.
TI  - Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
JA  - Cancer Res.
PY  - 2003///
VL  - 63
SP  - 4342
EP  - 4346
ER  -

TY  - JOUR
AU  - Kerbel, R. S.
AU  - Kamen, B. A.
TI  - The anti-angiogenic basis of metronomic chemotherapy
JA  - Nature Rev. Cancer
PY  - 2004///
VL  - 4
SP  - 423
EP  - 436
M3  - 10.1038/nrc1369
N1  - 10.1038/nrc1369
UR  - http://dx.doi.org/10.1038/nrc1369
ER  -

TY  - JOUR
AU  - Kim, J. J.
AU  - Tannock, I. F.
TI  - Repopulation of cancer cells during therapy: an important cause of treatment failure
JA  - Nature Rev. Cancer
PY  - 2005///
VL  - 5
SP  - 516
EP  - 525
M3  - 10.1038/nrc1650
N1  - 10.1038/nrc1650
UR  - http://dx.doi.org/10.1038/nrc1650
ER  -

TY  - JOUR
AU  - Jain, R. K.
TI  - Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
JA  - Science
PY  - 2005///
VL  - 307
SP  - 58
EP  - 62
M3  - 10.1126/science.1104819
N1  - 10.1126/science.1104819
UR  - http://dx.doi.org/10.1126/science.1104819
ER  -

TY  - JOUR
AU  - Winkler, F.
TI  - Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
JA  - Cancer Cell
PY  - 2004///
VL  - 6
SP  - 553
EP  - 563
M3  - 10.1016/j.ccr.2004.10.011
N1  - 10.1016/j.ccr.2004.10.011
UR  - http://dx.doi.org/10.1016/j.ccr.2004.10.011
ER  -

TY  - JOUR
AU  - Willett, C. G.
TI  - Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
JA  - Nature Med.
PY  - 2004///
VL  - 10
SP  - 145
EP  - 147
M3  - 10.1038/nm988
N1  - 10.1038/nm988
UR  - http://dx.doi.org/10.1038/nm988
ER  -

TY  - JOUR
AU  - Siemann, D. W.
AU  - Chaplin, D. J.
AU  - Horsman, M. R.
TI  - Vascular-targeting therapies for treatment of malignant disease
JA  - Cancer
PY  - 2004///
VL  - 100
SP  - 2491
EP  - 2499
M3  - 10.1002/cncr.20299
N1  - 10.1002/cncr.20299
UR  - http://dx.doi.org/10.1002/cncr.20299
ER  -

TY  - JOUR
AU  - Ferrara, N.
AU  - Hillan, K. J.
AU  - Gerber, H. P.
AU  - Novotny, W.
TI  - Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
JA  - Nature Rev. Drug Discov.
PY  - 2004///
VL  - 3
SP  - 391
EP  - 400
M3  - 10.1038/nrd1381
N1  - 10.1038/nrd1381
UR  - http://dx.doi.org/10.1038/nrd1381
ER  -

TY  - JOUR
AU  - Miller, K. D.
TI  - Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
JA  - J. Clin. Oncol.
PY  - 2005///
VL  - 23
SP  - 792
EP  - 799
ER  -

TY  - JOUR
AU  - Johnson, D. H.
TI  - Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
JA  - J. Clin. Oncol.
PY  - 2004///
VL  - 22
SP  - 2184
EP  - 2191
M3  - 10.1200/JCO.2004.11.022
N1  - 10.1200/JCO.2004.11.022
UR  - http://dx.doi.org/10.1200/JCO.2004.11.022
ER  -

TY  - JOUR
AU  - Smith, J. K.
AU  - Mamoon, N. M.
AU  - Duhe, R. J.
TI  - Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy
JA  - Oncol. Res.
PY  - 2004///
VL  - 14
SP  - 175
EP  - 225
ER  -

TY  - JOUR
AU  - Herbst, R. S.
TI  - Phase I study of recombinant human endostatin in patients with advanced solid tumors
JA  - J. Clin. Oncol.
PY  - 2002///
VL  - 20
SP  - 3792
EP  - 3803
M3  - 10.1200/JCO.2002.11.061
N1  - 10.1200/JCO.2002.11.061
UR  - http://dx.doi.org/10.1200/JCO.2002.11.061
ER  -

TY  - GEN
AU  - Garner, A.
TI  - Pathobiology of Ocular Disease
PY  - 1994///
SP  - 1625
EP  - 1710
ER  -

TY  - JOUR
AU  - Ruckman, J.
TI  - 2[prime]-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain
JA  - J. Biol. Chem.
PY  - 1998///
VL  - 273
SP  - 20556
EP  - 20567
M3  - 10.1074/jbc.273.32.20556
N1  - 10.1074/jbc.273.32.20556
UR  - http://dx.doi.org/10.1074/jbc.273.32.20556
ER  -

TY  - JOUR
AU  - Chen, Y.
TI  - Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen
JA  - J. Mol. Biol.
PY  - 1999///
VL  - 293
SP  - 865
EP  - 881
M3  - 10.1006/jmbi.1999.3192
N1  - 10.1006/jmbi.1999.3192
UR  - http://dx.doi.org/10.1006/jmbi.1999.3192
ER  -

TY  - JOUR
AU  - Kerbel, R. S.
TI  - Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches
JA  - Cancer Metastasis Rev.
PY  - 2001///
VL  - 20
SP  - 79
EP  - 86
M3  - 10.1023/A:1013172910858
N1  - 10.1023/A:1013172910858
UR  - http://dx.doi.org/10.1023/A:1013172910858
ER  -

TY  - JOUR
AU  - Sweeney, C. J.
AU  - Miller, K. D.
AU  - Sledge, G. W., 
TI  - Resistance in the anti-angiogenic era: nay-saying or a word of caution?
JA  - Trends Mol. Med.
PY  - 2003///
VL  - 9
SP  - 24
EP  - 29
M3  - 10.1016/S1471-4914(02)00007-2
N1  - 10.1016/S1471-4914(02)00007-2
UR  - http://dx.doi.org/10.1016/S1471-4914(02)00007-2
ER  -

TY  - JOUR
AU  - Yu, J. L.
AU  - Rak, J. W.
AU  - Coomber, B. L.
AU  - Hicklin, D. J.
AU  - Kerbel, R. S.
TI  - Effect of p53 status on tumor response to antiangiogenic therapy
JA  - Science
PY  - 2002///
VL  - 295
SP  - 1526
EP  - 1528
M3  - 10.1126/SCIENCE.1068327
N1  - 10.1126/SCIENCE.1068327
UR  - http://dx.doi.org/10.1126/SCIENCE.1068327
ER  -

TY  - JOUR
AU  - Glade Bender, J.
AU  - Cooney, E. M.
AU  - Kandel, J. J.
AU  - Yamashiro, D. J.
TI  - Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
JA  - Drug Resist. Updat.
PY  - 2004///
VL  - 7
SP  - 289
EP  - 300
ER  -

TY  - JOUR
AU  - Orimo, A.
TI  - Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
JA  - Cell
PY  - 2005///
VL  - 121
SP  - 335
EP  - 348
M3  - 10.1016/j.cell.2005.02.034
N1  - 10.1016/j.cell.2005.02.034
UR  - http://dx.doi.org/10.1016/j.cell.2005.02.034
ER  -

TY  - JOUR
AU  - Lewis, C.
AU  - Murdoch, C.
TI  - Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies
JA  - Am. J. Pathol.
PY  - 2005///
VL  - 167
SP  - 627
EP  - 635
ER  -

TY  - JOUR
AU  - Guo, W.
AU  - Giancotti, F. G.
TI  - Integrin signalling during tumour progression
JA  - Nature Rev. Mol. Cell. Biol.
PY  - 2004///
VL  - 5
SP  - 816
EP  - 826
M3  - 10.1038/nrm1490
N1  - 10.1038/nrm1490
UR  - http://dx.doi.org/10.1038/nrm1490
ER  -

TY  - JOUR
AU  - Hida, K.
TI  - Tumor-associated endothelial cells with cytogenetic abnormalities
JA  - Cancer Res.
PY  - 2004///
VL  - 64
SP  - 8249
EP  - 8255
M3  - 10.1158/0008-5472.CAN-04-1567
N1  - 10.1158/0008-5472.CAN-04-1567
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-04-1567
ER  -

TY  - JOUR
AU  - Streubel, B.
TI  - Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas
JA  - N. Engl. J. Med.
PY  - 2004///
VL  - 351
SP  - 250
EP  - 259
M3  - 10.1056/NEJMoa033153
N1  - 10.1056/NEJMoa033153
UR  - http://dx.doi.org/10.1056/NEJMoa033153
ER  -

TY  - JOUR
AU  - Ferrara, N.
AU  - Alitalo, K.
TI  - Clinical applications of angiogenic growth factors and their inhibitors
JA  - Nature Med.
PY  - 1999///
VL  - 5
SP  - 1359
EP  - 1364
M3  - 10.1038/70928
N1  - 10.1038/70928
UR  - http://dx.doi.org/10.1038/70928
ER  -

TY  - JOUR
AU  - Simons, M.
TI  - Angiogenesis: where do we stand now?
JA  - Circulation
PY  - 2005///
VL  - 111
SP  - 1556
EP  - 1566
M3  - 10.1161/01.CIR.0000159345.00591.8F
N1  - 10.1161/01.CIR.0000159345.00591.8F
UR  - http://dx.doi.org/10.1161/01.CIR.0000159345.00591.8F
ER  -

TY  - JOUR
AU  - Lederman, R. J.
TI  - Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
JA  - Lancet
PY  - 2002///
VL  - 359
SP  - 2053
EP  - 2058
M3  - 10.1016/S0140-6736(02)08937-7
N1  - 10.1016/S0140-6736(02)08937-7
UR  - http://dx.doi.org/10.1016/S0140-6736(02)08937-7
ER  -

TY  - JOUR
AU  - Henry, T. D.
TI  - The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis
JA  - Circulation
PY  - 2003///
VL  - 107
SP  - 1359
EP  - 1365
M3  - 10.1161/01.CIR.0000061911.47710.8A
N1  - 10.1161/01.CIR.0000061911.47710.8A
UR  - http://dx.doi.org/10.1161/01.CIR.0000061911.47710.8A
ER  -

TY  - JOUR
AU  - Heinl-Green, A.
TI  - The efficacy of a /`master switch gene/' HIF-1[alpha] in a porcine model of chronic myocardial ischaemia
JA  - Eur. Heart J.
PY  - 2005///
VL  - 26
SP  - 1327
EP  - 1332
M3  - 10.1093/eurheartj/ehi223
N1  - 10.1093/eurheartj/ehi223
UR  - http://dx.doi.org/10.1093/eurheartj/ehi223
ER  -

TY  - JOUR
AU  - Rafii, S.
AU  - Lyden, D.
TI  - Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration
JA  - Nature Med.
PY  - 2003///
VL  - 9
SP  - 702
EP  - 712
M3  - 10.1038/nm0603-702
N1  - 10.1038/nm0603-702
UR  - http://dx.doi.org/10.1038/nm0603-702
ER  -

TY  - JOUR
AU  - Tateishi-Yuyama, E.
TI  - Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial
JA  - Lancet
PY  - 2002///
VL  - 360
SP  - 427
EP  - 435
M3  - 10.1016/S0140-6736(02)09670-8
N1  - 10.1016/S0140-6736(02)09670-8
UR  - http://dx.doi.org/10.1016/S0140-6736(02)09670-8
ER  -

TY  - JOUR
AU  - Romond, E. H.
TI  - Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer
JA  - N. Engl. J. Med.
PY  - 2005///
VL  - 353
SP  - 1673
EP  - 1684
M3  - 10.1056/NEJMoa052122
N1  - 10.1056/NEJMoa052122
UR  - http://dx.doi.org/10.1056/NEJMoa052122
ER  -

TY  - JOUR
AU  - Morgan, B.
TI  - Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies
JA  - J. Clin. Oncol.
PY  - 2003///
VL  - 21
SP  - 3955
EP  - 3964
M3  - 10.1200/JCO.2003.08.092
N1  - 10.1200/JCO.2003.08.092
UR  - http://dx.doi.org/10.1200/JCO.2003.08.092
ER  -

TY  - JOUR
AU  - LeCouter, J.
TI  - Identification of an angiogenic mitogen selective for endocrine gland endothelium
JA  - Nature
PY  - 2001///
VL  - 412
SP  - 877
EP  - 884
M3  - 10.1038/35091000
N1  - 10.1038/35091000
UR  - http://dx.doi.org/10.1038/35091000
ER  -

TY  - JOUR
AU  - Samson, M.
TI  - Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis
JA  - J. Clin. Endocrinol. Metab.
PY  - 2004///
VL  - 89
SP  - 4078
EP  - 4088
M3  - 10.1210/jc.2003-032024
N1  - 10.1210/jc.2003-032024
UR  - http://dx.doi.org/10.1210/jc.2003-032024
ER  -

TY  - JOUR
AU  - Webb, T.
TI  - Work on breast cancer stem cells raises questions about treatment strategies
JA  - J. Natl. Cancer Inst.
PY  - 2003///
VL  - 95
SP  - 774
EP  - 775
ER  -

TY  - JOUR
AU  - Jones, R. J.
AU  - Matsui, W. H.
AU  - Smith, B. D.
TI  - Cancer stem cells: are we missing the target?
JA  - J. Natl. Cancer Inst.
PY  - 2004///
VL  - 96
SP  - 583
EP  - 585
ER  -

TY  - JOUR
AU  - Ponti, D.
TI  - Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties
JA  - Cancer Res.
PY  - 2005///
VL  - 65
SP  - 5506
EP  - 5511
M3  - 10.1158/0008-5472.CAN-05-0626
N1  - 10.1158/0008-5472.CAN-05-0626
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-05-0626
ER  -